Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | CDC25B | P30305 | 4/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.40 |
| ▸ | PTPRC | P08575 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | MAOA | P21397 | 4/20 | 0.40 |
| ▸ | IDO1 | P14902 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | PTPN22 | Q9Y2R2 | 2/20 | 0.40 |
| ▸ | APAF1 | O14727 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL216271 | 0.86 | MAOA (0.42) | MEN1KMT2ACDC25BPTPN1PTPRC | |
| SCHEMBL8366579 | 0.74 | CDC25B (0.32) | MEN1KMT2ACDC25BMAOAIDO1 | |
| SCHEMBL577831 | 0.70 | CDC25B (0.58) | MEN1KMT2ACDC25BPTPRCMAPT | |
| SCHEMBL223194 | 0.67 | IDO1 (0.48) | MEN1KMT2ACDC25BPTPN1PTPRC | |
| SCHEMBL6052798 | 0.62 | PTPN1 (0.58) | MEN1KMT2ACDC25BPTPN1PTPRC | |
| Anthraquinone SCHEMBL29358690 | 0.61 | MEN1 (1.00) | MEN1KMT2ACDC25BPTPRCMAPT | |
| Anthraquinone SCHEMBL14943 | 0.61 | MEN1 (1.00) | MEN1KMT2ACDC25BPTPRCMAPT | |
| Anthraquinone SCHEMBL1901249 | 0.61 | MEN1 (1.00) | MEN1KMT2ACDC25BPTPRCMAPT | |
| Anthraquinone SCHEMBL10905960 | 0.59 | MEN1 (0.92) | MEN1KMT2ACDC25BPTPRCMAPT | |
| Anthraquinone SCHEMBL20299926 | 0.59 | MEN1 (0.92) | MEN1KMT2ACDC25BPTPRCMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039503-B2 | Lapachone compounds and methods of use thereof | ARQULE, INC. (US) | 2011-10-18 | — | — | US | claimed |
| US-20110105470-A1 | Novel Lapachone Compounds And Methods of Use Thereof | ARQULE, INC. (US) | 2011-05-05 | — | — | US | claimed |
| US-7902354-B2 | Lapachone compounds and methods of use thereof | ARQULE, INC. (US) | 2011-03-08 | — | — | US | claimed |
| US-20090105166-A1 | Novel lapachone compounds and methods of use thereof | ARQULE, INC. | 2009-04-23 | — | — | US | claimed |
| EP-2035435-A1 | NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2009-03-18 | — | — | EP | claimed |
| WO-2007139569-A1 | NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2007-12-06 | — | — | WO | claimed |
| US-20120021432-A1 | Phosphorylated NF45 Biomarkers, Antibodies And Methods Of Using Same | ARQULE, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2011130644-A2 | PHOSPHORYLATED NF45 BIOMARKERS, ANTIBODIES AND METHODS OF USING SAME | ARQULE, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| US-8039503-B2 | Lapachone compounds and methods of use thereof | ARQULE, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110105470-A1 | Novel Lapachone Compounds And Methods of Use Thereof | ARQULE, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-7902354-B2 | Lapachone compounds and methods of use thereof | ARQULE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20090105166-A1 | Novel lapachone compounds and methods of use thereof | ARQULE, INC. | 2009-04-23 | — | — | US | disclosed |
| EP-2035435-A1 | NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007139569-A1 | NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105470-A1 | Novel Lapachone Compounds And Methods of Use Thereof | BAD, NQO1, CASP3 | MEN1 1674/4885KMT2A 3413/4885CDC25B 33/4885 |
| US-20120021432-A1 | Phosphorylated NF45 Biomarkers, Antibodies And Methods Of Using Same | NFKB1, NFKBIA, CDC45 | MEN1 2791/4885KMT2A 2912/4885CDC25B 2679/4885 |
| US-20090105166-A1 | Novel lapachone compounds and methods of use thereof | BAD, NQO1, CASP3 | MEN1 1674/4885KMT2A 3413/4885CDC25B 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.